CTRI/2022/11/047234已完成2 期
An open-label, randomized, balanced, two-treatment, two-sequence, two-period, cross-over, single-dose, oral bioequivalence study of Dapagliflozin 10mg and Vildagliptin Sustained Release tablets 100 mg (T) Manufactured by Eris Lifesciences Ltd, India with Zomelis-D (Dapagliflozin 10mg and Vildagliptin Sustained Release tablets 100 mg) (R) Manufactured by Exemed Pharmaceuticals., India in normal healthy, adult human subjects under fasting condition
Eris Lifesciences Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •Volunteers who accept for participating in this study must:
- •1. Healthy, adult human, subjects aged between 18-45 years (both inclusive) weighing at least 50 kg at the time of screening.
- •2. Having a Body Mass Index (BMI) between 18.50 to 30.00 kg/m2 (both inclusive) at the time of screening.
- •3. Normal or clinically insignificant findings during screening, medical history, medical examination, laboratory evaluations, 12 lead ECG and X-ray chest (posterior-anterior view) recordings.
- •4. Able to comply with the study procedures, in the opinion of the principal investigator.
- •5. Compliance with study specific restrictions and prohibitions.
- •6. Able to give voluntary written informed consent for participation in the trial.
- •7. Preferably non smoker and non alcoholic.
- •8. In case of Female subjects:
- •Female subjects who are of child bearing potential and are surgically sterilized at least 6 months prior to study participation.
- •Female subjects who are of childbearing potential and are willing to use a suitable and effective double barrier contraceptive method or non-hormonal intra uterine device during the study.
- •Female subjects who are tested negative for serum pregnancy test at the time of check-in.
- •Female subjects who are tested negative for urine pregnancy test at the time of screening.
- •Female subjects who has surgically sterilized partner (for at least 6 months).
排除标准
- •If any subject is having any of the following conditions, then exclude him/her from participation in this study:
- •1.Known hypersensitivity or idiosyncratic reaction to the study drug or any related drug.
- •2.History or presence of any disease or disorder known to influence bone metabolism, compromise the hemopoietin, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal, musculoskeletal or any other body system.
- •3.Systolic blood pressure less than 90 mmHg or more than 140 mmHg at the time of screening. Minor deviations (2-4 mmHg) may be acceptable at the discretion of the physician/investigator.
- •4.Diastolic blood pressure less than 60 mmHg or more than 90 mmHg at the time of screening. Minor deviations (2-4 mmHg) may be acceptable at the discretion of the physician/investigator.
- •5.Pulse rate below 60 beats/minute or above 100 beats/minute at the time of screening.
- •6.Respiratory rate below 12 or above 20 breaths per minute at the time of screening.
- •7.Body temperature below 96.2o F or above 99.8 o F at the time of screening.
- •8.SpO2 less than 94% @ RA at the time of screening.
- •9.Ingestion of any medicine at any time within 14 days prior to IP administration
- •10.in period I. In any such case subject selection will be at the discretion of the principal investigator.
- •11.Habit of consuming high caffeine (more than 5 cups of coffee or tea/day).
- •12.Smokers who smoke >9 cigarettes per day.
- •13.Alcoholic who consumes >21units of alcohol in a week.
- •14.History of dehydration from diarrhea, vomiting or any other reason within a period of 24.00 hours prior to study check-in.
- •15.An unusual or abnormal diet within 48.00 hours prior to study check-in, whatever reason e.g. because of fasting due to religious reasons.
- •16.The presence of clinically significant abnormal laboratory values during screening.
- •17.Use of any recreational drugs or history of drug addiction or testing positive in pre-study urine drug screening and Urine alcohol test.
- •18.A history of difficulty with donating blood or having donated blood in the preceding 90 days prior to the start of the study.
- •19.Subject who has participated in any other clinical study involving drug administration and collection of blood samples in the 90 days preceding the start of the study.
- •20.Difficulty in swallowing capsule/tablet.
- •21.Positive HIV, VDRL/RPR, Hepatitis B and C tests.
- •22.Subjects who have used any drugs or substances known to be strong inhibitors or inducers of Cytochrome P450 enzymes within 14 days prior to IP administration in period I.
- •23.History of undiagnosed vaginal bleeding (for females only).
- •24.Female subjects who demonstrates a positive pregnancy during screening or currently breast-feeding.
- •25.Female volunteer who has used implanted or injected hormonal contraceptives anytime during the 6 months prior to study or used hormonal contraceptives within 14 days before dosing.
研究者
相似试验
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, parallel group trial of HMR1766 assessing the efficacy and safety of 3 doses of HMR1766 (25, 100, 200 mg OD) versus placebo with cilostazol, 100 mg BID as a calibrator, administered for 26 weeks in patients with Peripheral Arterial Disease (PAD) Fontaine stage II. - ACCELAPeripheral Arterial Disease (PAD) Fontaine stage II (intermittent claudication)MedDRA version: 8.1Level: LLTClassification code 10022562Term: Intermittent claudicationEUCTR2006-004275-35-FRsanofi-aventis recherche & développement550
进行中（未招募）
不适用
A study to determine the appropriate dose(s) of Dupilumab (REGN668)in adult patients with moderate to severe atopic dermatitis (eczema)Atopic dermatitsMedDRA version: 16.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2012-003651-11-PLRegeneron Pharmaceuticals, Inc.240
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group trial of HMR1766 assessing the efficacy and safety of 3 doses of HMR1766 (25, 100, 200 mg OD) versus placebo with cilostazol, 100 mg BID as a calibrator, administered for 26 weeks in patients with Peripheral Arterial Disease (PAD) Fontaine stage II. - ACCELAPeripheral Arterial Disease (PAD) Fontaine stage II (intermittent claudication)MedDRA version: 8.1Level: LLTClassification code 10022562Term: Intermittent claudicationEUCTR2006-004275-35-ATsanofi-aventis recherche & développement550
进行中（未招募）
1 期
Efficacy and safety of dexketoprofen trometamol and tramadol hydrochloride combination on moderate to severe acute pain in patients with acute low back paiow back painMedDRA version: 21.0Level: LLTClassification code 10024891Term: Low back painSystem Organ Class: 100000004859EUCTR2019-003656-37-ESMenarini International Operations Luxembourg SA538
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with traditional DMARD therapy in patients with moderate to severe active rheumatoid arthritis and an inadequate response to current DMARD therapy.Rheumatoid ArthritisEUCTR2004-005210-37-DEF. Hoffmann La-Roche AG1,200